文献速递毛发、甲与色素性疾病

淋巴细胞性原发性瘢痕性脱发代谢失调综述:关联与治疗启示

A Review of Metabolic Dysregulation in Lymphocytic Cicatricial Alopecia: Exploring the Connections and Therapeutic Implications.
PubMed 文献 · J Invest Dermatol · 2025-03-18

本文综述淋巴细胞性原发性瘢痕性脱发(LPCA)与代谢失调(尤其是糖尿病和血脂异常)的关联。流行病学研究显示LPCA患者代谢紊乱患病率增加,分子研究揭示受累毛囊中PPARγ信号和AMPK激活等代谢通路改变,且这些改变可能早于炎症。靶向这些通路的初步治疗(如吡格列酮和二甲双胍)显示希望,但需进一步研究。

要点

  • LPCA患者中代谢紊乱(糖尿病、血脂异常)患病率增加。
  • 毛囊中PPARγ信号和AMPK激活改变可能先于炎症,提示代谢失调为原发触发因素。
  • 吡格列酮和二甲双胍等靶向代谢通路的初步治疗显示改善脂代谢和减轻炎症的潜力。

核心结论

  • LPCA与代谢失调存在显著关联,代谢功能障碍可能是原发触发因素而非继发效应。
  • 靶向代谢通路的治疗(如吡格列酮、二甲双胍)在正常化脂代谢和减轻炎症方面显示初步希望,但各亚型临床疗效需进一步研究。
  • 建议对LPCA患者进行代谢筛查,并开发更全面的代谢靶向治疗。

研究设计与样本

  • 本文为综述,检索并汇总了关于LPCA与代谢失调关联的流行病学研究、分子 investigation 及初步治疗证据。

主要发现

  • 流行病学研究显示LPCA患者中代谢紊乱(特别是糖尿病和血脂异常)患病率增加。
  • 分子研究揭示受累毛囊中代谢通路改变,包括过氧化物酶体增殖物激活受体γ(PPARγ)信号紊乱和腺苷酸活化蛋白激酶(AMPK)激活改变,这些机制与其他纤维化疾病中观察到的平行。
  • 这些代谢通路改变似乎先于炎症变化,提示代谢功能障碍为原发触发因素。

关键数值与推荐

  • 初步治疗靶向这些通路(如吡格列酮和二甲双胍)在正常化脂代谢和减少炎症方面显示有希望的结果。
  • 新兴治疗可能性包括胰高血糖素样肽-1(GLP-1)激动剂。

临床怎么用

  • 建议对LPCA患者进行代谢筛查(如糖尿病和血脂异常)。
  • 考虑代谢靶向治疗作为潜在的综合治疗策略,但需进一步临床验证。

局限性

  • 靶向治疗在LPCA各亚型中的临床疗效需进一步研究。
  • 综述未报告具体样本量、效应量或统计学显著性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lymphocytic primary cicatricial alopecia (LPCA) is an inflammatory disorder characterized by permanent hair follicle destruction and fibrosis. Recent evidence suggests a significant link between LPCA and metabolic dysregulation, particularly diabetes and dyslipidemia. This review examines the emerging role of metabolism in LPCA pathogenesis and its implications for novel therapeutic approaches. Epidemiologic studies demonstrate increased prevalence of metabolic disorders among patients with LPCA, whereas molecular investigations reveal altered metabolic pathways in affected hair follicles, including disruptions in peroxisome proliferator-activated receptor γ signaling and adenosine monophosphate-activated protein kinase activation, mechanisms that parallel those observed in other fibrotic diseases. These pathways appear to precede inflammatory changes, suggesting metabolic dysfunction as a primary trigger rather than a secondary effect. Preliminary treatments targeting these pathways, such as pioglitazone and metformin, have shown promising results in normalizing lipid metabolism and reducing inflammation, although their clinical efficacy across LPCA subtypes requires further investigation. The review also explores emerging therapeutic possibilities, including glucagon-like peptide-1 agonists. Understanding the interplay between metabolic disturbances, fibrosis, and inflammation in the pathogenesis of LPCA offers new avenues for both research and treatment. This paradigm shift suggests the need for metabolic screening in patients with LPCA and highlights the potential for developing more comprehensive, metabolism-targeted therapies to improve outcomes in these challenging hair disorders.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Bao A, Bordone LA, Aguh C, et al. A Review of Metabolic Dysregulation in Lymphocytic Cicatricial Alopecia: Exploring the Connections and Therapeutic Implications. J Invest Dermatol. 2025. PMID: 40100177. doi:10.1016/j.jid.2025.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。